Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have
different age-specific characteristics and definitions. Trials on surfactant for ARDS in children …

Respiratory distress syndrome (RDS) was recognized to be caused by primary surfactant
deficiency almost 70 years ago and continuous positive airway pressure was introduced …

Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral …

Pulmonary surfactant is a complex lipoprotein mixture secreted into the alveolar lumen by
type 2 pneumocytes, which is composed by tens of different lipids (approximately 90% of its …

The knowledge about surfactant biology is now deeper and recent research has allowed to
clarify its role in several human lung disorders. The balance between surfactant production …

The clinical benefits of using exogenous pulmonary surfactant (EPS) as a carrier of
budesonide (BUD), a non-halogenated corticosteroid with a broad anti-inflammatory effect …

The inflammation present in acute respiratory distress syndrome (ARDS) and thereby
associated injury to the alveolar-capillary membrane and pulmonary surfactant can …

Childhood pneumonia, often caused by acute upper respiratory tract infections or bronchitis,
is one of the leading causes of mortality in children. Nebulized inhalation, as a low-risk …

To investigate the association between serum miR-338-3p levels and neonatal acute
respiratory distress syndrome (ARDS) and its mechanism. The relative miR-338-3p …

Neonatal acute respiratory distress syndrome (ARDS) is a relatively new diagnosis. Specific
treatment, beyond managing the underlying disease, generally relies on lung protective …